Astrocyte

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Retrieved on: 
Thursday, July 20, 2023
PK, GFAP, Glial fibrillary acidic protein, Clinical trial, SC, Biogen, The New England Journal of Medicine, BIIB, Pathology, PET, Brain, Biomarker, Clarity, Plasma, Eisai, AAIC, Fluid mechanics, Amyloid, Headquarters, Corporation, Astrocyte, Neurogranin, Lecanemab, AD, FDA, Conference, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Medical imaging, Pharmaceutical industry, Alzheimer's disease, CSF

TOKYO and CAMBRIDGE, Mass., July 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI®) treatment showed reductions in amyloid-beta (Aβ) pathology and downstream biomarker changes. This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023. The U.S. Food and Drug Administration (FDA) granted traditional approval for LEQEMBI for the treatment of Alzheimer's disease (AD) on July 6, 2023.

Key Points: 
  • This analysis, and the latest findings on the lecanemab subcutaneous (SC) formulation currently under development, were presented at the Alzheimer's Association International Conference (AAIC) 2023.
  • These outcomes suggested lecanemab impacts A/T/N+ biomarkers involved in the AD pathophysiology and exerts biological effects that demonstrate slowing of disease progression.
  • In an exposure/bioavailability and modeling study comparing intravenous (IV) and subcutaneous (SC) dosing of lecanemab, the bioavailability of SC dosing of lecanemab was shown to be approximately 50% of that of IV dosing.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

Retrieved on: 
Monday, July 17, 2023
Neuron, Intellectual property, Epilepsy, Neurological disorder, Proiphys, Brain, Doctor of Philosophy, Astrocyte, DSM-IV codes, Cell, Acquisition, Parkinson's disease, Organoid, Neuropathic pain, OTC, Drug discovery, R, ALS, Pharmaceutical industry

NEW ORLEANS and CHERRY HILL, N.J., July 17, 2023 /PRNewswire/ -- AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio's StemoniX subsidiary. The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders. The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers. These rights would terminate in the event the transaction is not consummated.

Key Points: 
  • The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders.
  • The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers.
  • The StemoniX microBrain technology is a highly scalable iPSC-derived high-throughput neural screening platform coupled with advanced bioanalytical software for phenotypic drug discovery.
  • "We believe that AxoSim is the perfect partner for our StemoniX microBrain technology," said Andrew LaFrence, President, Chief Executive Officer and Chief Financial Officer of Vyant Bio.

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

Retrieved on: 
Monday, July 10, 2023
Retina, Tissue, Smell, Neuron, TNFR1, TNF, GFAP, Ear, Axon, Pathology, Brain, Biomarker, Multiple sclerosis, Astrocyte, Remyelination, MS, Nose, Regeneration, Pharmacotherapy, Hearing, Drug development, Biology, Mouse, Microglia, Allograft inflammatory factor 1, Skin, Disease, Medical imaging

Boca Raton, Florida, July 10, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces important findings from data presented at The 16th European Meeting on Glial Cells in Health and Disease.  The conference runs July 8-12 in Berlin, Germany.

Key Points: 
  • Any damage to the myelin sheath compromises axon function preventing nerve cells from communicating and can result in nerve cell death.
  • Although the pathology of demyelination is easy to see, the biology of demyelination and remyelination is poorly understood.
  • The third surprise is that traditional biomarkers of astroglial and microglial activation, GFAP and Iba1 respectively, are increased in these myelin-promoting glial cells.
  • Therapeutic modulation of solTNF-TNFR1 signaling selectively in microglia promotes remyelination in the cortical grey matter.

Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease

Retrieved on: 
Wednesday, June 28, 2023
State, Central nervous system, Therapy, Human brain, Cell, Astrocyte, CNS, Drug discovery, Disease, XVI, Fine chemical

BOSTON, June 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.

Key Points: 
  • BOSTON, June 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.
  • Title: NETSseq Provides Deep Molecular Insight Into Astrocyte Biology, Identifying Complex Regional and State Dependent Heterogeneity in the Human Brain
    Overview: Cerevance’s proprietary NETSseq platform has generated highly reproducible molecular profiles of many specific neuronal and glial cell types (>60) from human brains.
  • Using machine learning techniques, the regional and state dependent heterogeneity in human astrocytes is better understood and leveraged to help to define the role of these cells in disease and identify cell type specific targets for drug discovery.

FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit

Retrieved on: 
Thursday, June 1, 2023
Astrocyte, Drug development, Central nervous system, Medium (website), IPSC, Pericyte, Stroke, 3D, Blood–brain barrier, DSM-IV codes, Pharmacokinetics, Hope, Physiology, Traffic barrier, Brain, Research, Cell, CNS, Neuroscience, Dementia, Animal, ICEL Psalter, Permeability, Patient, Drug discovery, Microglia, Neurological disorder, Migraine, WHO, IPS, Meningitis, World Health Organization, Medical imaging

The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.

Key Points: 
  • The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.
  • The iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready to use, human iPSC-derived cell model that has barrier integrity and functionality consistent with in vivo physiological properties.
  • The iCell Blood-Brain Barrier Isogenic Kit is commercially available and will begin shipping by the end of June 2023.
  • To learn more about FUJIFILM Cellular Dynamics’ blood-brain barrier cellular model, you can visit https://www.fujifilmcdi.com/icell-blood-brain-barrier-kit-coming-soon/ .

Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

Retrieved on: 
Thursday, May 18, 2023
Infection, Neuron, DNA, GBA1, Human, Central nervous system, Capsid, Spinal cord, TRACER, Traffic barrier, Brain, Research, Gene expression, Tropism, RNA, Antibody, AAV, CNS, Astrocyte, ESGCT, BBB, Transgene, Rita Raave, DRG, Mouse, Liver, Sf9 (cells), Disability studies, Therapy, Glucocerebrosidase, Neurology, Oligonucleotide, Family, Society, Vaccine, Substantia nigra, Putamen

These results are being presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023, in Los Angeles.

Key Points: 
  • These results are being presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023, in Los Angeles.
  • “These data demonstrate that our TRACER capsid discovery platform is able to generate brain-penetrant capsids in a highly reproducible manner,” said Todd Carter, Chief Scientific Officer of Voyager Therapeutics.
  • In these studies, VCAP-102 demonstrated de-targeting of the dorsal root ganglia (DRG) and liver.
  • Researchers identified a new capsid called VCAP-103, which demonstrated enhanced brain and spinal cord transduction in marmosets and African green monkeys.

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

Retrieved on: 
Monday, April 10, 2023
Science, Neurology, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Adenosine A1 receptor, University, Chicago Innovation Awards, Therapy, Interview, American Heart Association, COVID-19, Yale Center for Environmental Law & Policy, University of Warwick, Innovation, Multimedia, Daubert v. Merrell Dow Pharmaceuticals, Inc., Progress, Associate, Splenic infarction, Data analysis, Publication, Patient, Brain, Risk, Primate, Russell, Cerebrovascular disease, University of Texas Health Science Center at San Antonio, J. Anthony Lukas Work-in-Progress Award, Nursing care plan, Rush University Medical Center, Adenosine, Pharmaceutical industry, Astrocyte, Stroke

The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”

Key Points: 
  • The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.”
    This press release features multimedia.
  • The study showed compelling benefits for AST-004 treatment slowing stroke lesion growth, preserving at risk penumbra tissue, and substantially reducing the amount of brain tissue lost to the stroke.
  • The Progress and Innovation Award is given to the publication’s first author and is comprised of a cash prize and a trophy.
  • “The ongoing excitement of endovascular reperfusion has heralded a resurgence of scientific development aimed at improving acute stroke outcomes.

Vizgen Launches the MERSCOPE® PanNeuro Cell Type Predesigned Panel

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Pharmaceutical, Health, Stem Cells, Neuron, Allen Institute for Brain Science, Bureau of Oceans and International Environmental and Scientific Affairs, BioRxiv, Research, Cell, Astrocyte, Doctor of Philosophy, Allen Institute, Mobile phone, Medical imaging

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the launch of its highly anticipated MERSCOPE ® PanNeuro Cell Type Predesigned Panel, enabling cellular and sub-cellular analysis of neuronal signaling, activity and connectivity in the mouse brain.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the launch of its highly anticipated MERSCOPE ® PanNeuro Cell Type Predesigned Panel, enabling cellular and sub-cellular analysis of neuronal signaling, activity and connectivity in the mouse brain.
  • The PanNeuro Cell Type Panel is the first of Vizgen’s predesigned 500 gene panels, providing a readily accessible tool for researchers working in neuroscience.
  • This comprehensive cell typing panel was constructed using the Allen Mouse Brain Atlas1, published literature2-6, and published Vizgen Mouse Brain datasets7.
  • Many key marker genes used in the new PanNeuro panel were well validated in the Whole Mouse Brain Atlas.

Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2023 ADDF-Harrington Scholar Award

Retrieved on: 
Monday, April 3, 2023
RFP, Neurovascular bundle, Drug development, Request, Pericyte, Alzheimer's disease, Request for proposal, University, Hypoxia (medical), University Hospitals Cleveland Medical Center, Dementia, Research, Brain, Astrocyte, Alzheimer's Drug Discovery Foundation, United Kingdom, Pharmaceutical industry

CLEVELAND, April 3, 2023 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.

Key Points: 
  • CLEVELAND, April 3, 2023 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award .
  • The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.
  • Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are strongly encouraged to apply.
  • This award provides a combination of financial support and expert drug development guidance to provide optimal support for moving research beyond the bench to the bedside.

Synthego Introduces CRISPR Discovery Partners to Streamline CRISPR-Driven Drug Discovery Research

Retrieved on: 
Thursday, March 16, 2023
Research, CRISPR, Machine learning, Ready 2 Go, Drug discovery, Worldwide Angel, Ecosystem, Partnership, Microglia, Immortalised cell line, Global health, Suretrack Contracts Services, Astrocyte, IPSC, Neuron, CDMO, Therapy, Pharmaceutical industry, Fine chemical

REDWOOD CITY, Calif., March 16, 2023 /PRNewswire/ -- Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services. The ecosystem brings together high-value partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx to offer a coordinated solution for CRISPR-driven drug discovery. 

Key Points: 
  • REDWOOD CITY, Calif., March 16, 2023 /PRNewswire/ -- Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners , designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services.
  • The ecosystem brings together high-value partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx to offer a coordinated solution for CRISPR-driven drug discovery.
  • Synthego's CRISPR Discovery Partners include:
    Arctoris, a tech-enabled drug discovery service company, combines wet lab automation and machine learning with a world-class team of experienced drug discovery researchers to enable the accelerated development of small molecule, biologics, and cell therapy assets.
  • BrainXell provides differentiation services to generate high-purity, iPSC-derived human neurons, astrocytes, and microglia for research use with a focus on drug discovery.